A carregar...
Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal change disease (MCD). MCD is thought to be T-...
Na minha lista:
| Publicado no: | Can J Kidney Health Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5433659/ https://ncbi.nlm.nih.gov/pubmed/28540057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2054358117698667 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|